Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 15/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10193014 | 0.95 | BACE1 (0.46) | BACE1SIRT2SIRT1SIRT3HPGD | |
| SCHEMBL10192928 | 0.93 | BACE1 (0.46) | BACE1SIRT2SIRT1SIRT3NPC1 | |
| SCHEMBL10193785 | 0.93 | BACE1 (0.48) | BACE1SIRT2SIRT1SIRT3NPC1 | |
| SCHEMBL10193935 | 0.92 | BACE1 (0.45) | BACE1SIRT2SIRT1SIRT3 | |
| SCHEMBL10193824 | 0.92 | BACE1 (0.45) | BACE1 | |
| SCHEMBL10192932 | 0.90 | BACE1 (0.46) | BACE1SIRT2SIRT1SIRT3NPC1 | |
| SCHEMBL10155847 | 0.90 | BACE1 (0.59) | BACE1 | |
| SCHEMBL10193927 | 0.90 | BACE1 (0.49) | BACE1SIRT2SIRT1SIRT3NPC1 | |
| SCHEMBL10193920 | 0.88 | BACE1 (0.45) | BACE1 | |
| SCHEMBL10192921 | 0.88 | BACE1 (0.46) | BACE1SIRT2SIRT1SIRT3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015961-A1 | ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015961-A1 | ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | BACE1, BACE2, APP | BACE1 1/4885SIRT2 3238/4885SIRT1 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.